Ao Liu,Huilin Xie,Fangyan Tian,Peiyuan Bai,Haobo Weng,Yu Liu,Wen Liu,Lu Tang,Hongmin You,Nianwei Zhou,Xianhong Shu,Ao LiuHuilin XieFangyan TianPeiyuan BaiHaobo WengYu LiuWen LiuLu TangHongmin YouNianwei ZhouXianhong ShuDepartment of Echocardiography,Zhongshan Hospital,Fudan University,Shanghai Institute of Cardiovascular Diseases,China. (A.L.,H.X.,F.T.,H.W.,Y.L.,W.L.,L.T.,N.Z.)Department of Cardiology,Zhongshan Hospital,Fudan University,Shanghai Institute of Cardiovascular Diseases,China. (A.L.,H.X.,P.B.,H.W.,X.S.)Department of Ultrasound Medicine,The Affiliated Hospital of Guizhou Medical University,Guiyang,China (F.T.).Department of Cardiology,Changhai Hospital,Naval Medical University,Shanghai,China (H.Y.).Department of Echocardiography,Shanghai Xuhui District Central Hospital,China (X.S.).

Abstract:Hypertension, Ahead of Print. BACKGROUND:Cardiac hypertrophy and subsequent heart failure impose a considerable burden on public health worldwide. Impaired protein degradation, especially endo-lysosome-mediated degradation of membrane proteins, is associated with cardiac hypertrophy progression. CHMP4C (charged multivesicular body protein 4C), a critical constituent of multivesicular bodies, is involved in cellular trafficking and signaling. However, the specific role of CHMP4C in the progression of cardiac hypertrophy remains largely unknown.METHODS:Mouse models with CHMP4C knockout or cardiadc-specific overexpression were subjected to transverse aortic constriction surgery for 4 weeks. Cardiac morphology and function were assessed through histological staining and echocardiography. Confocal imaging and coimmunoprecipitation assays were performed to identify the direct target of CHMP4C. An EGFR (epidermal growth factor receptor) inhibitor was administrated to determine whether effects of CHMP4C on cardiac hypertrophy were EGFR dependent.RESULTS:CHMP4C was significantly upregulated in both pressure-overloaded mice and spontaneously hypertensive rats. Compared with wild-type mice, CHMP4C deficiency exacerbated transverse aortic constriction–induced cardiac hypertrophy, whereas CHMP4C overexpression in cardiomyocytes attenuated cardiac dysfunction. Mechanistically, the effect of CHMP4C on cardiac hypertrophy relied on the EGFR signaling pathway. Fluorescent staining and coimmunoprecipitation assays confirmed that CHMP4C interacts directly with EGFR and promotes lysosome-mediated degradation of activated EGFR, thus attenuating cardiac hypertrophy. Notably, an EGFR inhibitor canertinib counteracted the exacerbation of cardiac hypertrophy induced by CHMP4C knockdown in vitro and in vivo.CONCLUSIONS:CHMP4C represses cardiac hypertrophy by modulating lysosomal degradation of EGFR and is a potential therapeutic candidate for cardiac hypertrophy.

RNA-binding protein CELF1 promotes cardiac hypertrophy via interaction with PEBP1 in cardiomyocytes

Inhibition of TRPC1 Prevents Cardiac Hypertrophy Via NF-κB Signaling Pathway in Human Pluripotent Stem Cell-Derived Cardiomyocytes.

HNF4α ubiquitination mediated by Peli1 impairs FAO and accelerates pressure overload-induced myocardial hypertrophy

Low density lipoprotein receptor-related protein 1 regulates cardiac hypertrophy induced by pressure overload

Beta-Catenin/tcf/lef1 Can Directly Regulate Phenylephrine-Induced Cell Hypertrophy and Anf Transcription in Cardiomyocytes.

Transcriptome analysis reveals EBF1 ablation-induced injuries in cardiac system

CREB1 transcription-activated lncRNA PVT1 promotes cardiac fibrosis via miR-145/HCN1 axis

CBL aggravates Ang II-induced cardiac hypertrophy via the VHL/HIF-1α pathway

PPARα activation inhibits endothelin-1-induced cardiomyocyte hypertrophy by prevention of NFATc4 binding to GATA-4.

HypERlnc attenuates angiotensin II‐induced cardiomyocyte hypertrophy via promoting SIRT1 SUMOylation‐mediated activation of PGC‐1α/PPARα pathway in AC16 cells

3′ untranslated region of Ckip-1 inhibits cardiac hypertrophy independently of its cognate protein

Cardiac Ankyrin Repeat Protein Attenuates Cardiac Hypertrophy by Inhibition of ERK1/2 and TGF-β Signaling Pathways.

Activation of peroxisome proliferator-activated receptor gamma inhibits endothelin-1-induced cardiac hypertrophy via the calcineurin/NFAT signaling pathway

Overexpression of PEP-19 suppresses angiotensin II-induced cardiomyocyte hypertrophy.

RNF207 exacerbates pathological cardiac hypertrophy via post-translational modification of TAB1

Cytokine receptor-like factor 1 (CRLF1) promotes cardiac fibrosis via ERK1/2 signaling pathway

The transcription factor EBF1 non-cell-autonomously regulates cardiac growth and differentiation

Cardiomyocyte‐specific Peli1 contributes to the pressure overload‐induced cardiac fibrosis through miR‐494‐3p‐dependent exosomal communication

ESCRT-III Component CHMP4C Attenuates Cardiac Hypertrophy by Targeting the Endo-Lysosomal Degradation of EGFR

Polypyrimidine tract binding protein 1 exacerbates cardiac fibrosis by regulating fatty acid‐binding protein 5

Leukocyte Immunoglobulin-Like Receptor B4 Protects Against Cardiac Hypertrophy Via SHP-2-dependent Inhibition of the NF-κB Pathway